Diana Liu – General Manager, Roche Hong Kong & Macau
Roche has a strong presence in Hong Kong with a local footprint dating back to 1971. Diana Liu, general manager of the Swiss pharma’s Hong Kong & Macau affiliate, outlines…
Company information:
Hybribio is a leading provider for in vitro diagnostic assays in Greater China with fully integrated operation chain from R&D, manufacturing, sales & marketing to after-sales technical support service. As of year 2016, over 16 million tests of our HPV Genotyping test has been performed in China. Furthermore, we are the sole company collaborating with the Ministry of Health in Chinese Government to establish the first HPV database system in China. Based on technological platforms such as our proprietary flow-through hybridization technology, real-time PCR technology, and high throughput sequencing, our two major R&D lines – infectious pathogens detection and genetic disease detection – include human papillomavirus (HPV), thalassemia, G6PD, hearing loss susceptibility, phenylketonuria (PKU), and early cancer detection etc. Our products have been widely used in the fields of clinical detection, large scale screening, and prenatal and neonatal management.
Address: 27/F, Bonham Trade Centre, 50 Bonham Strand, Sheung Wan, Hong Kong
Tel.: (+852) 2851 8029
Website: http://hybribio.com/
Email: marketing@hybribio.com
Roche has a strong presence in Hong Kong with a local footprint dating back to 1971. Diana Liu, general manager of the Swiss pharma’s Hong Kong & Macau affiliate, outlines…
Managing director of Otsuka Pharmaceutical Hong Kong Koji Ueda explains the Japanese company’s long-standing presence in Hong Kong, which dates back to 1956, the affiliate’s 50-50 split between pharmaceuticals and…
Industry veteran Krish Sundaresan, GM for Hong Kong & Macau at Pfizer for the past two and a half years, shares his experience navigating the shifting dynamics brought on by…
Tony Cheng, managing director and general manager for Hong Kong & Macau at Merck Healthcare walks us through the challenges and opportunities arising from Hong Kong’s transformation, Merck’s strong local…
Last Autumn, the Hong Kong government announced a plan to create a one-stop-shop clinical trial institute across the Greater Bay Area (GBACTI) as part of its plan to promote biomedical…
VMS Group was founded in 2006 and since then has built close relationships with a handful of large anchor investors, including some of the largest families in Hong Kong. Apart…
Haematological oncologist Dr Raymond Liang, gives his take on the adoption and challenges of CAR-T therapy in Hong Kong, the necessity of collaboration with mainland China for patient referrals and…
Hong Kong Exchanges and Clearing Limited (HKEX) chief executive Nicolas Aguzin has stepped down after a term fraught with upheaval. Having survived COVID-19 isolation, under Aguzin HKEX was confronted with…
Although well-established as Asia’s leading financial services and trading hub, Hong Kong has never truly been globally competitive in the innovation and technology space, despite piecemeal initiatives to bolster its…
While much of PharmaBoardroom’s recent report on Hong Kong and the Greater Bay Area looks at how Hong Kong is attempting to position itself as a development and financing hub…
Hong Kong provides some of the best and most efficient healthcare in Asia, with Hong Kongers living to over 85 on average (compared to 83 in Singapore and 78 in…
A decade on from its launch, the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) initiative has made some significant wins but remains some way from fulfilling the vision of a fully…
See our Cookie Privacy Policy Here
